AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 67 min read$AMPH

Amphastar Pharmaceuticals, Inc. (AMPH): Results of Operations and Financial Condition

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amph-20260806xex99d1.htm EX-99.1 EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per sh

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$AMPH
Neutral
medium confidence
Mentioned
$AMPH
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMPHNeutralMed
01

Why it matters

Traders can update near-term expectations for Amphastar’s earnings trajectory using the reported revenue, EPS, gross margin drivers, and the disclosed BAQSIMI milestone payment timing in Q3 2026.

02

Market read

The filing supplies fresh quarterly numbers plus specific product drivers (pricing, competition, unit volume timing) and a concrete future cash payment tied to BAQSIMI sales.

03

What to watch

The $100M milestone payment due in Q3 2026 to Eli Lilly for BAQSIMI could be a near-term earnings and cash-flow overhang that is easy to miss versus the GAAP and non-GAAP EPS figures.

Relevance 7/10Novelty 6/10Timing: after-hours earnings filing, conference call at 2:00 p.m. PT today

Background

This is an SEC Form 8-K (Item 2.02) with Amphastar’s Q2 2026 financial results and product-level revenue commentary.

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Amphastar reported Q2 ended June 30, 2026 results, including net revenues of $183.9M and GAAP EPS of $0.67.

Expected impact

Near-term volatility possible around earnings interpretation, but direction depends on whether investors focus on revenue growth, margin expansion, and the upcoming $100M milestone payment.

Evidence & confidence

The filing provides concrete financial results and segment drivers, plus a specific third-quarter 2026 cash outflow trigger ($100M) related to the Eli Lilly BAQSIMI milestone.

Market effects

Sector

Provides read-through on generic/proprietary injectable and inhalation product pricing, discounting, and competitive dynamics for specialty pharma peers.

Regional

Limited, company-specific impact centered on Amphastar’s Rancho Cucamonga manufacturing expansion and operating expenses.

Global

Low; primarily US-focused product portfolio and contract milestone mechanics.

Counterpoint

What could challenge this read

Investors may discount the headline revenue growth if gross-to-net discount changes and competitive pressure on key products (BAQSIMI, epinephrine, glucagon) are viewed as structurally recurring.

Key entities

  • company
    Amphastar Pharmaceuticals, Inc.

    NASDAQ-listed biopharmaceutical company reporting Q2 2026 results and product revenue drivers.

  • counterparty
    Eli Lilly & Company

    Contract milestone partner for BAQSIMI asset purchase agreement; milestone triggers a $100M payment due in Q3 2026.

Read at source← All news

Related articles

JUL 9
$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

medicaldaily.com5 min
JUN 10
$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash

finance.yahoo.com7 min
JUN 2
$AMPHMedAI 8/10

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Piper Sandler cut its price target for Amphastar Pharmaceuticals (NASDAQ: AMPH) from $25 to $21 while keeping a Neutral rating, TheFly reported May 11. The firm cited limited visibility on when pipeline programs will produce meaningful results. Amphastar’s May 7 Q1 ended March 31, 2026 net revenues were $171.2M; GAAP EPS $0.14 and adjusted EPS $0.42.

finance.yahoo.com4 min
AUG 6
$XPOFHigh

Xponential Fitness, Inc. (XPOF): Results of Operations and Financial Condition

Xponential Fitness, Inc. (XPOF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d328551dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Xponential Fitness, Inc. Announces Second Quarter 2026 Financial Results - North America system-wide sales 1 of $437.3 million were flat year-over-year - Opened 67 gross new studios and sold 53 franchise licenses in Q2 2026

SEC EDGAR 8-K6 min
AUG 6
$OSGMed

OCTAVE SPECIALTY GROUP INC (OSG): Results of Operations and Financial Condition

OCTAVE SPECIALTY GROUP INC (OSG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a03-0532q26ex991osgpressre.htm EX-99.1 Document Exhibit 99.1 Octave Specialty Group Reports Second Quarter 2026 Results • Insurance Distribution Segment ◦ Total revenue grew 77% to $58 million ◦ Organic revenue growth equaled 44% ◦ Ne t loss to Shareholders totaled $(4)

SEC EDGAR 8-K6 min
AUG 6
$BMNMMed

BIMINI CAPITAL MANAGEMENT, INC. (BMNM): Results of Operations and Financial Condition

BIMINI CAPITAL MANAGEMENT, INC. (BMNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_980652.htm EXHIBIT 99.1 ex_980652.htm Exhibit 99.1 BIMINI CAPITAL MANAGEMENT ANNOUNCES Second QUARTER 2026 RESULTS VERO BEACH, Fla., ( August 6, 2026 ) – Bimini Capital Management, Inc. (OTCQX: BMNM), (“Bimini Capital,” “Bimini,” or the “Company”), today announced re

SEC EDGAR 8-K5 min